Make a check list, check whether this medicine is in our home or whether it has been recommended by our doctor.
Please don't use it.
Please read very carefully inform all your friends and family members.-please make sure u forward it everyone u know DANGEROUS DRUGS HAVE BEEN GLOBALLY DISCOVERED but are available iin INDIA.The most common ones are action 500 and Nimulid.
PHENOLPHTHANEIN
LAXATIVE.
REASON FOR BAN - CANCER
BRAND NAME - AGAROL
OXYPHENBUTAZONE
NON-STEROIDAL ,ANTIINFLAMMATORY DRUG.
REASON FOR BAN - BONE MARROW DEPRESSION
BRAND NAME -SIORIL
PLAEASE SPREAD THE INFORMATION ..... IF U CAN..... FOR BETTER FUTURE.
Please don't use it.
Please read very carefully inform all your friends and family members.-please make sure u forward it everyone u know DANGEROUS DRUGS HAVE BEEN GLOBALLY DISCOVERED but are available iin INDIA.The most common ones are action 500 and Nimulid.
PHENYLPROPANOLAMINE
COLD AND COUGH.
REASON FOR BAN - STROKE
BRAND NAME - VICKS ACTION 500
COLD AND COUGH.
REASON FOR BAN - STROKE
BRAND NAME - VICKS ACTION 500
NIMESULIDE
PAIN KILLER, FEVER.
PAIN KILLER, FEVER.
REASON FOR BAN - LIVER FAILURE
BRAND NAME - NISE, NIMULID
ANALGIN
THIS IS A PAIN KILLER.
REASON FOR BAN - BONE MARROW DEPRESSION
BRAND NAME - NOVALGIN
THIS IS A PAIN KILLER.
REASON FOR BAN - BONE MARROW DEPRESSION
BRAND NAME - NOVALGIN
DROPERIDOL
ANTI-DEPRESSANT.
REASON FOR BAN - IRREGULAR HEART BEAT
BRAND NAME -DROPERIDOL
ANTI-DEPRESSANT.
REASON FOR BAN - IRREGULAR HEART BEAT
BRAND NAME -DROPERIDOL
FURAZOLIDONE
ANTIDIARRHOEAL.
REASON FOR BAN - CANCER
BRAND NAME - FUROXONE, LOMOFEN
ANTIDIARRHOEAL.
REASON FOR BAN - CANCER
BRAND NAME - FUROXONE, LOMOFEN
PHENOLPHTHANEIN
LAXATIVE.
REASON FOR BAN - CANCER
BRAND NAME - AGAROL
OXYPHENBUTAZONE
NON-STEROIDAL ,ANTIINFLAMMATORY DRUG.
REASON FOR BAN - BONE MARROW DEPRESSION
BRAND NAME -SIORIL
PIPERAZINE
ANTIWORMS.
REASON FOR BAN - NERVE DAMAGE
BRAND NAME - PIPERAZINE
ANTIWORMS.
REASON FOR BAN - NERVE DAMAGE
BRAND NAME - PIPERAZINE
PLAEASE SPREAD THE INFORMATION ..... IF U CAN..... FOR BETTER FUTURE.
No comments:
Post a Comment